Lilly Stands By Experimental Diabetes Drug, Despite Questions About Data
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Despite early evidence that one of its experimental diabetes drugs may cause higher heart and blood pressure rates, Eli Lilly remains adamant that development should continue